Dyadic International Inc. DYAI
- Market cap
- $17.4M
- P/E
- 0.0×
Follow DYAI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.32 | 1.23 | 1.38 | 1.77 | 2.51 | 3.15 | 1.12 | 1.20 | 0.93 | 0.71 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 1.85 | 1.81 | 2.29 | 7.30 | 10.98 | 8.78 | 4.98 | 2.40 | 2.67 | 2.14 |
High Price
|
|||
| — | — | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 5 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Revenue/Emp
|
|||
| 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
Revenue
|
|||
| 100.00% | 10.31% | 20.70% | 13.17% | 11.05% | 19.11% | 27.54% | 31.84% | 65.82% | 24.93% |
Gross Margin
|
|||
| 1 | (2) | (7) | (8) | (9) | (13) | (10) | (7) | (6) | (7) |
EBT
|
|||
| 100.00% | (290.41%) | (517.01%) | (493.59%) | (580.19%) | (543.73%) | (332.23%) | (234.42%) | (166.20%) | (238.31%) |
EBT Margin
|
|||
| 0 | (2) | (6) | (8) | (9) | (13) | (10) | (7) | (6) | (7) |
Net Income
|
|||
| — | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.02 | 0.03 | 0.05 | 0.06 | 0.06 | 0.09 | 0.10 | 0.10 | 0.12 | 0.09 |
Revenue/Sh
|
|||
| (0.10) | (0.07) | (0.21) | (0.31) | (0.34) | (0.47) | (0.34) | (0.24) | (0.20) | (0.23) |
Earnings/Sh
|
|||
| (0.17) | (0.06) | (0.16) | (0.21) | (0.24) | (0.41) | (0.28) | (0.23) | (0.14) | (0.17) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.17) | (0.06) | (0.16) | (0.21) | (0.24) | (0.41) | (0.28) | (0.23) | (0.14) | (0.17) |
Free CF/Sh
|
|||
| 1.58 | 1.73 | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | 0.20 | 0.08 | 0.04 |
Book Value/Sh
|
|||
| 37 | 29 | 28 | 27 | 27 | 28 | 28 | 29 | 29 | 33 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.00 | 63.08 | 40.39 | 83.21 | 92.26 | 52.35 | 13.36 | 15.80 | 14.68 | 9.92 |
PS Ratio
|
|||
| 0.00 | 0.96 | 1.23 | 3.90 | 5.20 | 6.84 | 3.53 | 7.79 | 20.77 | 24.88 |
PB Ratio
|
|||
| (8.35) | 0.25 | 8.57 | 62.85 | 74.10 | 43.92 | 9.04 | 13.33 | 13.45 | 8.78 |
EV/Sales
|
|||
| 0.00 | (0.15) | (2.46) | (17.93) | (17.76) | (9.27) | (3.23) | (5.65) | (11.51) | (4.67) |
EV/FCF
|
|||
| (6) | (2) | (4) | (6) | (7) | (11) | (8) | (7) | (4) | (6) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| (6) | (2) | (4) | (6) | (7) | (11) | (8) | (7) | (4) | (6) |
FCF
|
|||
| 57 | 49 | 42 | 34 | 28 | 18 | 11 | 6 | 7 | 6 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 5 | 5 |
Total Debt
|
|||
| (56) | (48) | (41) | (34) | (29) | (20) | (13) | (7) | (4) | (4) |
Net Debt
|
|||
| 58 | 50 | 42 | 36 | 28 | 18 | 11 | 6 | 2 | 1 |
Sh' Equity
|
|||
| 0.00% | (8.42%) | (12.10%) | (20.58%) | (27.62%) | (50.89%) | (55.61%) | (61.97%) | (64.01%) | (74.11%) |
ROA
|
|||
| 26.74% | 20.70% | (380.11%) | (353.37%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (12.14%) | (3.97%) | (12.32%) | (21.22%) | (29.00%) | (55.81%) | (66.05%) | (80.11%) | (139.16%) | (397.80%) |
ROE
|
|||
Dyadic International Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PTN Palatin Technologies, Inc. | $17.5M | 2.4× | Compare |
| ALLR Allarity Therapeutics, Inc. | $17.3M | 0.0× | Compare |
| ANEB Anebulo Pharmaceuticals, Inc. | $17.6M | 0.0× | Compare |
| AKTX Akari Therapeutics PLC | $17.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LPCN Lipocine Inc. | $17.2M | 0.0× | Compare |
| KTTA Pasithea Therapeutics Corp. | $17.2M | 0.0× | Compare |
| ACGN Aceragen, Inc. | $17.1M | 0.0× | Compare |
| BCDA BioCardia, Inc. | $16.2M | 0.0× | Compare |
Dyadic International Inc. (DYAI) key facts
- Dyadic International Inc. (DYAI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
- Dyadic International Inc. reported a net loss of $7.4 million, or a loss of $0.23 per share, for fiscal 2025.
- As of September 25, 2026, DYAI traded at $0.42, a market capitalization of $17.4 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.0× sales.
- Return on equity was −397.8% and debt-to-equity -2.11.
Dyadic International Inc. (DYAI) Latest News
19 Aug
Dyadic International Inc. (DYAI) held its Q2 2026 earnings call, covering quarterly financial results, operational updates and future outlook. Q2 earnings call delivers financial results and guidance that may shift short-term sentiment without fundamentally changing company trajectory.
14 Aug
Dyadic International Inc. reported second quarter results including revenue, expenses and operational updates for the period. Quarterly results deliver updated financial metrics that can shift near-term investor sentiment and valuation.
13 Aug
Dyadic International Inc (DYAI) reported a 52% revenue surge in its Q2 2026 earnings call highlights. 52% revenue surge in quarterly results signals strong growth that can significantly shift company trajectory and investor views.
Dyadic International Inc. (DYAI) released its Q2 2026 earnings call summary. Q2 earnings updates deliver financial results that can moderately shift market views and company outlook.
12 Aug
Dyadic International Inc. (DYAI) announced second quarter 2026 financial results showing accelerating commercialization momentum across key business areas. Earnings release with accelerating commercialization signals major positive shifts in revenue trajectory and investor sentiment.
4 Aug
Dyadic International Inc. enters new strategic development agreement expanding commercial non-animal dairy pipeline. New agreement supports pipeline expansion with moderate potential effects on growth trajectory.
28 Jul
Dyadic developed stable C1 cell lines and produced purified Scripps-designed Bundibugyo Ebola antigens from plasmids in approximately 15 days. Rapid Ebola antigen production highlights C1 platform efficiency but remains an early-stage technical milestone without immediate revenue or market shift.
16 Jul
Dyadic International Inc. launches new proprietary industrial enzyme program to expand bio-industrial pipeline. New enzyme program expands pipeline and supports ongoing product innovation.
7 Jul
Dyadic International advances its C1 platform via ongoing global collaborations that validate the technology and expand commercial opportunities. Ongoing global collaborations validate the C1 platform and expand commercial reach, materially improving long-term prospects.
29 Jun
Dyadic International Inc. expands intellectual property protection and business development activities in Japan. IP expansion and business development in Japan strengthens Dyadic competitive position and growth prospects.
22 Jun
Dyadic International's President & COO outlines commercialization strategy for its protein platform across multi-billion-dollar markets. Interview details Dyadic strategy to target multi-billion-dollar markets with protein platform.
15 Jun
Dyadic reports rising interest in its C1 biomanufacturing platform driven by Ebola preparedness work and expanding commercial adoption. Accelerated platform interest tied to Ebola readiness and commercial uptake points to major growth prospects for Dyadic.
2 Jun
Dyadic International Inc. (DYAI) released its Q1 2026 earnings call transcript covering financial results, operations and future outlook. Q1 2026 earnings transcript supplies performance data and guidance that can shift near-term investor sentiment for DYAI.
28 May
Dyadic International Inc. collaborates with Scripps Research on rapid-response Hantavirus antibody and vaccine development. Hantavirus antibody and vaccine collaboration advances Dyadic's infectious disease programs and production technology positioning.
20 May
Dyadic International Inc. released first quarter results detailing revenues, net losses and operational updates on its protein production platforms and partnerships. Quarterly results directly inform financial health metrics and short-term investor sentiment for the company.
14 May
Dyadic International Inc. (DYAI) Q1 2026 earnings call highlights revenue surge and strategic advancements boosting future prospects. Revenue surge and strategic initiatives indicate major positive shifts in financial performance and competitive positioning for DYAI.
Dyadic International, Inc. released Q1 2026 earnings call summary covering financial results, operational progress, and future outlook. Q1 earnings call summary reveals financial performance and strategic updates with moderate influence on trajectory.
13 May
Dyadic International Inc. (DYAI) released the transcript of its Q1 2026 earnings conference call. Q1 2026 earnings call transcript discloses financial results, operational updates, and guidance significantly influencing DYAI's future performance and investor sentiment.
Dyadic International Inc. (DYAI) announced first quarter 2026 financial results and highlighted recent company progress. Quarterly financial results combined with progress highlights signal potential shifts in financial health and strategic positioning, significantly impacting investor sentiment and market performance.
30 Mar
Dyadic International Inc. (DYAI) introduces AlbuFree DX, a new product advancing their biotechnology platform. Launching AlbuFree DX marks a significant product innovation that could boost DYAI's market position and investor interest.
28 Mar
Analysts expect Dyadic International Inc. (NASDAQ:DYAI) to reach breakeven in the near future. Analyst breakeven forecast signals improved financial outlook, potentially boosting investor sentiment without guaranteeing major shifts.
25 Mar
Dyadic International Inc. (DYAI) Q4 2025 earnings call highlights navigating transition amid strategic shifts, financial updates, and operational developments. Earnings call highlights detail strategic transitions and financial results poised to significantly influence DYAI's future performance and investor sentiment.
Dyadic International, Inc. released Q4 2025 earnings call summary covering financial results, operational updates, pipeline progress, and future guidance. Q4 earnings call summaries disclose year-end financials and strategic plans that significantly shape investor expectations and stock trajectory.
Dyadic International Inc. (DYAI) released its Q4 2025 earnings call transcript, covering quarterly financial results, business updates, and forward-looking statements. Q4 earnings transcript discloses financial performance, pipeline progress, and guidance that significantly shape investor expectations and stock trajectory.
Dyadic International Inc. (DYAI) announced 2025 financial results and highlighted recent company progress. Financial results disclosure and progress updates moderately affect financial performance and investor sentiment.
16 Mar
Dyadic Applied BioSolutions, part of Dyadic International Inc. (DYAI), announces a commercial distribution partnership with IBT Bioservices to expand market reach for its bio-based products. Commercial distribution partnership represents a major strategic move to enhance product commercialization and revenue potential for DYAI.
4 Mar
Dyadic International Inc. (DYAI) and Fermbox Bio launched their first product under an expanded collaboration: animal-origin-free recombinant DNase I (RNase-free). Launching the first product from an expanded biotech collaboration advances Dyadic's enzyme pipeline and commercialization potential.
2 Mar
Dyadic Applied BioSolutions and Inzymes ApS announce planned 2026 commercialization of a non-animal dairy enzyme after achieving a key development milestone. Milestone achievement advances non-animal dairy enzyme toward 2026 commercialization, strengthening Dyadic's product pipeline and market positioning.
17 Feb
Dyadic Applied BioSolutions and Proliant Health & Biologicals announce commercial launch of recombinant human albumin produced using Dyadic's C1 gene expression platform. Commercial launch of recombinant human albumin via strategic partnership enables new revenue stream and validates Dyadic's biomanufacturing technology.
22 Dec
Dyadic International Inc. has entered into multiple commercialization agreements aimed at expanding its product offerings and market reach. These agreements are expected to enhance the company's capabilities in biopharmaceutical development and manufacturing, potentially leading to increased revenue streams. The partnerships focus on leveraging Dyadic's proprietary technology to improve the efficiency and effectiveness of drug production. As a result, the company is positioning itself for growth in the competitive biotech landscape. The commercialization agreements are likely to significantly enhance Dyadic's market position and revenue potential.